| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by first author.
Page 2: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 301 | 2 | 13 | 649 1977 JOURNAL OF MEDICAL PRIMATOLOGY 6(5):319-324 BUTLER H EFFECT OF THALIDOMIDE ON A PROSIMIAN - GREATER GALAGO (GALAGO-CRASSICAUDATUS) | 3 | 5 |
| 302 | 3 | 5 | 331 1965 COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES 159(5):1059-& CAHEN CRR; DUPUIS R MALFORMATIONS VISCERALES PROVOQUEES PAR LE THALIDOMIDE CHEZ LE LAPIN | 0 | 0 |
| 303 | 0 | 0 | 28 1961 BRITISH MEDICAL JOURNAL 2(526):1223-& CAHILL PK NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 4 |
| 304 | 4 | 13 | 1144 1994 JOURNAL OF CHEMICAL CRYSTALLOGRAPHY 24(1):95-99 CAIRA MR; BOTHA SA; FLANAGAN DR POLYMORPHISM OF N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE (THALIDOMIDE) - STRUCTURAL CHARACTERIZATION OF A 2ND MONOCLINIC RACEMIC MODIFICATION | 0 | 2 |
| 305 | 71 | 96 | 1613 2000 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 58 | 99 |
| 306 | 13 | 16 | 1525 1999 CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
| 307 | 1 | 2 | 1780 2000 PALLIATIVE MEDICINE 14(1):77-78 Calder K; Bruera E Thalidomide for night sweats in patients with advanced cancer | 6 | 7 |
| 308 | 53 | 74 | 1343 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 21 | 26 |
| 309 | 8 | 10 | 1941 2001 HAEMATOLOGICA 86(10):1108-1109 Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M Thalidomide and thrombosis in patients with multiple myeloma | 10 | 11 |
| 310 | 0 | 0 | 938 1987 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 114(9):1176-1176 CAMBAZARD F; LAFFAY A; VEDRINNE JM; THIVOLET J NEUROLOGICAL COMPLICATIONS OF THALIDOMIDE - STUDY OF 55 DERMATOLOGY PATIENTS (WITH THE EXCEPTION OF HANSENS-DISEASE PATIENTS) | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 311 | 0 | 1 | 151 1962 LANCET 2(7262):937-& CAMERON JM; CHRISTIE GA THALIDOMIDE AND CONGENITAL ABNORMALITIES | 2 | 6 |
| 312 | 4 | 4 | 1624 2000 ARCHIVES OF DERMATOLOGY 136(12):1442-1443 Camisa C; Popovsky JL Effective treatment of oral erosive lichen planus with thalidomide | 6 | 11 |
| 313 | 0 | 0 | 1646 2000 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
| 314 | 2 | 12 | 1891 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):313-315 Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M Thalidomide in agnogenic and secondary myelofibrosis | 11 | 16 |
| 315 | 0 | 3 | 396 1966 LANCET 1(7447):1134-& CANT JS MINOR OCULAR ABNORMALITIES ASSOCIATED WITH THALIDOMIDE | 2 | 4 |
| 316 | 4 | 5 | 2222 2002 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212 Cany L; Fitoussi O; Boiron JM; Marit G Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma | 4 | 4 |
| 317 | 22 | 42 | 1522 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 10 | 25 |
| 318 | 0 | 0 | 72 1962 BRITISH MEDICAL JOURNAL (5305):673-& CAPENER N THALIDOMIDE BABIES | 0 | 0 |
| 319 | 20 | 25 | 2543 2003 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 1 |
| 320 | 12 | 43 | 2585 2004 BIOORGANIC & MEDICINAL CHEMISTRY 12(2):327-336 Capitosti SM; Hansen TP; Brown ML Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 321 | 10 | 44 | 2580 2004 ARCHIVES OF DERMATOLOGY 140(3):277-280 Caradona S; Jacobe H Thalidomide as a potential treatment for scleromyxedema | 0 | 0 |
| 322 | 0 | 0 | 2091 2002 BLOOD 100(11):385B-385B Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S Thalidomide induced neuropathy in patients treated for multiple myeloma. | 0 | 0 |
| 323 | 0 | 0 | 2361 2003 BLOOD 102(11):382B-383B Caravita T; Siniscalchi A; Niscola P; Santinelli S; Buccisano F; Montanaro M; De Fabritiis P; Amadori S Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma. | 0 | 0 |
| 324 | 9 | 15 | 2674 2004 MICROCHEMICAL JOURNAL 77(1):1-7 Cardoso CE; Martins ROR; Aucelio RQ Evaluation of a spectrofluorimetric method for the selective determination of thalidomide in pharmaceutical tablets, urine and blood serum | 0 | 0 |
| 325 | 0 | 0 | 1134 1994 CHEMISTRY IN BRITAIN 30(4):280-280 CAREY J THALIDOMIDE DEBATE - REPLY | 0 | 0 |
| 326 | 17 | 44 | 1205 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
| 327 | 5 | 6 | 1067 1992 LANCET 339(8805):1362-1362 CARMICHAEL AJ; KNIGHT A THALIDOMIDE - A RESTRICTED ROLE | 3 | 5 |
| 328 | 0 | 0 | 2062 2002 BLOOD 100(11):15B-15B Carneiro JDA; Garanito M; Halsman M; Matsumoto L; Odone V; del Giglio A Thalidomide as salvage therapy for acquired severe aplastice anemia (SAA) in children - Case report | 0 | 0 |
| 329 | 8 | 17 | 1298 1996 TERATOLOGY 54(6):273-277 Castilla EE; AshtonProlla P; BarredaMejia E; Brunoni D; Cavalcanti DP; CorreaNeto J; Delgadillo JL; Dutra MG; Felix T; Giraldo A; Juarez N; LopezCamelo JS; Nazer J; Orioli IM; Paz JE; Pessoto MA; PinaNeto JM; Quadrelli R; Rittler M; Rueda S; Saltos M; Sanchez O; Schuler L Thalidomide, a current teratogen in South America | 14 | 17 |
| 330 | 0 | 0 | 2381 2003 BLOOD 102(11):490B-490B Castro J; Davila J; Perez S; Flores L; Lopez A; Roman A; Pacheco E; Fernandex A; Fradera J; Garcia R; Merle S; Velez-Garcia E High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide (T) as maintenance in patients (P) with multiple myeloma (MM). | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 331 | 0 | 0 | 1668 2000 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
| 332 | 0 | 0 | 903 1985 NEW SOCIETY 74(1196):369-371 CAUDREY A THALIDOMIDE GENERATION | 0 | 0 |
| 333 | 8 | 10 | 2679 2004 NEUROLOGY 62(12):2291-2293 Cavaletti G; Beronio A; Reni L; Ghiglione E; Schenone A; Briani C; Zara G; Cocito D; Isoardo G; Ciaramitaro P; Plasmati R; Pastorelli F; Frigo M; Piatti M; Carpo M Thalidomide sensory neurotoxicity - A clinical and neurophysiologic study | 1 | 1 |
| 334 | 19 | 50 | 2412 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 12 | 15 |
| 335 | 8 | 8 | 2061 2002 BLOOD 100(6):2272-2273 Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy | 11 | 15 |
| 336 | 19 | 37 | 2628 2004 HAEMATOLOGICA 89(7):826-831 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; De Vivo A; Palareti G; Tura S; Baccarani M First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 337 | 0 | 0 | 2371 2003 BLOOD 102(11):448A-448A Cavo M; Zamagni E; Tosi P; Cellini C; de Vivo A; Cangini D; Tonelli M; Testoni N; Grafone T; Tacchetti P; Soverini S; Terragna C; Tura S; Baccarani M Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma. | 0 | 0 |
| 338 | 5 | 9 | 372 1966 CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL 8(6):299-& CAZORT RJ; SONG YK A TRIAL OF THALIDOMIDE IN PROGRESSIVE LEPRA REACTIONS | 9 | 11 |
| 339 | 11 | 60 | 1614 2000 AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 2 | 23 |
| 340 | 0 | 0 | 1290 1996 NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY 22(5):456-456 Chakrabarty A; Bridges LR Cerebral malformation in a patient with thalidomide related phocomelia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 341 | 3 | 6 | 991 1989 BRITISH MEDICAL JOURNAL 298(6665):6-6 CHAMBERLAIN G THE OBSTETRIC PROBLEMS OF THE THALIDOMIDE CHILDREN | 0 | 0 |
| 342 | 6 | 9 | 710 1979 TERATOLOGY 19(1):129-129 CHAMBERLAIN JG THALIDOMIDE AND LACK OF TERATOGENESIS IN LONG-EVANS RATS | 0 | 1 |
| 343 | 2 | 21 | 313 1965 ARZNEIMITTEL-FORSCHUNG 15(5):508-& CHAMPYHA.S ACTION DE LIMIDAZOLE SUR LES PREMIERS METABOLITES DE LA THALIDOMIDE - ETUDE DE LA SCISSION DU NOYAU PHTALIMIDE | 0 | 10 |
| 344 | 0 | 3 | 332 1965 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 260(15):4208-& CHAMPYHA.S IMIDAZOLE ET THALIDOMIDE . ETUDE SPECTRALE COMPAREE DES DEUX NOYAUX PHTALIMIDE ET GLUTARIMIDE | 0 | 4 |
| 345 | 0 | 6 | 333 1965 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 261(1):271-& CHAMPYHA.S LE GLUTARIMIDE ET LACTIVITE DE LA THALIDOMIDE . ETUDE SPECTRALE ETENDUE JUSQUE VERS 2050 A | 0 | 9 |
| 346 | 0 | 0 | 349 1965 PATHOLOGIE BIOLOGIE 13(23-2):1241-& CHAMPYHA.S LE GLUTARIMIDE ET LACTIVITE DE LA THALIDOMIDE . ETUDE SPECTRALE ETENDUE JUSQUE VERS 2050A | 0 | 0 |
| 347 | 1 | 33 | 419 1967 ARZNEIMITTEL-FORSCHUNG 17(9):1155-& CHAMPYHA.S CONJUGATED ACTION OF 2 NUCLEI OF THALIDOMIDE ON IMIDAZOLINE COMPOUNDS - HISTAMINE AND PURINE BASES | 0 | 4 |
| 348 | 0 | 5 | 215 1963 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 257(21):3138-& CHAMPYHATEM S SPECTROSCOPIE MOLECULAIRE - SUR LABSORPTION ULTRAVIOLETTE DU PHTALIMIDE ET DE LA THALIDOMIDE EN MILIEU ALCALIN | 3 | 6 |
| 349 | 0 | 0 | 2383 2003 BLOOD 102(11):675A-675A Chanan-Khan AA; Fallon A; Miller K; Bernstein ZP; Hernandez F; Alam A; McCarthy P; Mohr A; Czuczman MS Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial. | 0 | 0 |
| 350 | 0 | 0 | 2368 2003 BLOOD 102(11):389B-389B Chanan-Khan AA; Miller K; Srinivasan S; David S; McCarthy P; Alam A; Bernstein ZP; Czuczman MS Velcade (Vel), Doxil (R) (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM). | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 351 | 0 | 0 | 2352 2003 BLOOD 102(11):353B-353B Chanan-Khan AA; Stein L; David S; Takeshita K; Platt J; Miller K; Fallon A; Czuczman MS; Hawthorn L Thalidomide (T) induced in vivo changes in gene expression profile (GEP) of malignant chronic lymphocytic leukemia (CLL) cells. | 0 | 0 |
| 352 | 4 | 16 | 2249 2002 JOURNAL OF THE CHINESE CHEMICAL SOCIETY 49(3):383-385 Chang MY; Chang CH; Chen ST; Chang NC A synthesis of thalidomide | 0 | 9 |
| 353 | 4 | 19 | 2563 2003 SYNTHETIC COMMUNICATIONS 33(8):1375-1382 Chang MY; Chen ST; Chang NC A synthesis of racemic thalidomide | 0 | 4 |
| 354 | 17 | 30 | 906 1985 REVUE NEUROLOGIQUE 141(11):719-728 CHAPON F; LECHEVALIER B; DASILVA DC; RIVRAIN Y; DUPUY B; DESCHAMPS P THALIDOMIDE INDUCED NEUROPATHY | 5 | 8 |
| 355 | 8 | 20 | 401 1966 LANCET 1(7451):1373-& CHARD T; HELLMANN K IMMUNOSUPPRESSION BY THALIDOMIDE | 3 | 3 |
| 356 | 0 | 0 | 1203 1995 JOURNAL OF INVESTIGATIVE DERMATOLOGY 105(3):479-479 CHARUE D; CHAUVIN E; DUGUET C; REVUZ J; BAGOT M THALIDOMIDE DECREASES THE PRODUCTION OF GM-CSF AND TNF-ALPHA IN MIXED EPIDERMAL-CELL LYMPHOCYTE-REACTION | 2 | 2 |
| 357 | 18 | 24 | 1260 1996 EUROPEAN JOURNAL OF DERMATOLOGY 6(5):373-376 Charue D; Chauvin E; Duguet C; Revuz J; Bagot M Thalidomide decreases the production of GM-CSF and TNF-alpha in the mixed epidermal cell-lymphocyte reaction | 1 | 2 |
| 358 | 14 | 21 | 273 1964 BIOCHEMICAL PHARMACOLOGY 13(6):940-& CHAUDHARY KD; LEMONDE A EFFECT OF THALIDOMIDE ON TRIBOLIUM CONFUSUM DUVAL | 2 | 4 |
| 359 | 2 | 18 | 370 1966 CANCER RESEARCH 26(9P1):1884-& CHAUDHRY AP; SCHMUTZ JA EFFECTS OF PREDNISOLONE AND THALIDOMIDE ON INDUCED SUBMANDIBULAR GLAND TUMORS IN HAMSTERS | 0 | 1 |
| 360 | 0 | 6 | 382 1966 JOURNAL OF DENTAL RESEARCH 45(6P2):1767-& CHAUDHRY AP; SCHWARTZ S; SCHMUTZ JA EFFECTS OF CORTISONE AND THALIDOMIDE ON MORPHOGENESIS OF SECONDARY PALATE IN A/HEJ MICE | 0 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 361 | 0 | 0 | 1289 1996 NEUROLOGY 46(2):27003-27003 Chaudhry V; Cornblath D; Corse A; Freimer M; SimmonsOBrien E; Vogelsang G Thalidomide-induced neuropathy: Clinical and electrophysiological features | 0 | 0 |
| 362 | 21 | 29 | 2270 2002 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 6 | 7 |
| 363 | 30 | 32 | 1885 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
| 364 | 2 | 10 | 2684 2004 TRANSPLANTATION PROCEEDINGS 36(4):1018-1020 Chaves DNB; Petroianu A; Alberti LR; Pereira WA Effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in rabbits | 0 | 0 |
| 365 | 0 | 0 | 1506 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
| 366 | 2 | 5 | 1317 1997 BONE MARROW TRANSPLANTATION 19(1):95-96 Chen F; Tsang K; Liang R Thalidomide-responsive chronic pulmonary GVHD | 0 | 0 |
| 367 | 0 | 0 | 2206 2002 INTERNATIONAL JOURNAL OF CANCER :336-337 Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma | 0 | 0 |
| 368 | 18 | 24 | 993 1989 DRUG METABOLISM AND DISPOSITION 17(4):402-405 CHEN TL; VOGELSANG GB; PETTY BG; BRUNDRETT RB; NOE DA; SANTOS GW; COLVIN OM PLASMA PHARMACOKINETICS AND URINARY-EXCRETION OF THALIDOMIDE AFTER ORAL DOSING IN HEALTHY MALE-VOLUNTEERS | 77 | 81 |
| 369 | 0 | 0 | 1509 1999 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
| 370 | 3 | 13 | 1233 1996 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 123(6-7):375-377 Cherouati K; Claudy A; Souteyrand P; Cambazard F; Vaillant L; Moulin G; Crickx B; Morel P; Lamorelle A; Revuz J Thalidomide treatment of chronic erythema multiforme recurrent and continuous variants. A retrospective study of 26 patients. | 6 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 371 | 0 | 0 | 22 1961 BRITISH MEDICAL JOURNAL 2(525):1025-& CHEVENS LCF NEUROPATHY AFTER THALIDOMIDE | 2 | 3 |
| 372 | 7 | 17 | 2322 2003 APMIS 111:113-116 Chew M; Zhou J; Daugherty A; Eriksson T; Ellermann-Eriksen S; Hansen PR; Falk E Thalidomide inhibits early atherogenesis in apoE-deficient mice | 0 | 0 |
| 373 | 4 | 9 | 2473 2003 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
| 374 | 0 | 0 | 2435 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
| 375 | 8 | 24 | 1420 1998 BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 26 |
| 376 | 5 | 25 | 1178 1995 BRITISH JOURNAL OF CANCER 72(2):339-343 CHING LM; XU ZF; GUMMER BH; PALMER BD; JOSEPH WR; BAGULEY BC EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID | 25 | 41 |
| 377 | 0 | 0 | 1125 1994 BRITISH MEDICAL JOURNAL 308(6931):739-739 CHRISTIE B THALIDOMIDE VICTIMS WIN REVIEW OF COMPENSATION | 2 | 2 |
| 378 | 13 | 28 | 2606 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 1 | 1 |
| 379 | 0 | 0 | 2592 2004 BONE MARROW TRANSPLANTATION 33:S160-S161 Ciepluch H; Knopinska-Posluszny W; Czyz J; Hellmann A Employment of autologous transplantation of progenitor cells following effective treatment with thalidomide of patients with multiple myeloma resistant to conventional chemotherapy | 0 | 0 |
| 380 | 0 | 0 | 1376 1997 NATURE MEDICINE 3(1):8-8 Cimons M Thalidomide resurfaces for FDA consideration | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 381 | 7 | 10 | 2672 2004 MEDICINA CLINICA 122(15):595-596 Cistero B; Sala M; Soler A; Garcia N Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient | 0 | 0 |
| 382 | 14 | 32 | 2685 2004 UROLOGY 63(6):1061-1065 Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma | 0 | 0 |
| 383 | 0 | 0 | 2507 2003 JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
| 384 | 53 | 140 | 1919 2001 DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 13 |
| 385 | 11 | 15 | 2285 2002 REVUE DE MEDECINE INTERNE 23(7):651-656 Claudon A; Dietemann JL; De Compte AH; Hassler P Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in Langerhans cell histiocytosis. | 1 | 1 |
| 386 | 0 | 0 | 1218 1995 NEUROLOGY 45(4):A168-A168 CLAVELOU P; COLAMARINO R; DINCAN M; DEFFOND D; TOURNILHAC M; SOUTEYRAND P THALIDOMIDE-RELATED NEUROPATHY - A PROSPECTIVE, CLINICAL, ELECTROMYOGRAPHIC TRIAL | 1 | 1 |
| 387 | 0 | 0 | 75 1962 BRITISH MEDICAL JOURNAL (5308):857-& CLAY AA DEFORMITIES NOT DUE TO THALIDOMIDE | 0 | 0 |
| 388 | 6 | 20 | 842 1984 ARCHIVES OF DERMATOLOGY 120(3):338-341 CLEMMENSEN OJ; OLSEN PZ; ANDERSEN KE THALIDOMIDE NEUROTOXICITY | 41 | 59 |
| 389 | 0 | 0 | 1000 1989 MEDICINA CLINICA 92(15):571-571 CODINA C THALIDOMIDE 1989 | 1 | 1 |
| 390 | 2 | 3 | 2603 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Cohen LB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 391 | 0 | 1 | 1097 1993 GASTROENTEROLOGY 104(4):A683-A683 COHEN LB; PEAREN S; IAZZETTA J THALIDOMIDE FOR INFLAMMATORY BOWEL-DISEASE - A PRELIMINARY-REPORT | 0 | 0 |
| 392 | 1 | 5 | 1742 2000 JOURNAL OF CLINICAL ONCOLOGY 18(19):3453-3453 Cohen MH Thalidomide in the treatment of high-grade gliomas | 1 | 3 |
| 393 | 1 | 2 | 5 1960 AMERICAN JOURNAL OF PSYCHIATRY 116(11):1030-1031 COHEN S SLEEP REGULATION WITH THALIDOMIDE | 4 | 9 |
| 394 | 4 | 10 | 166 1962 NEW ENGLAND JOURNAL OF MEDICINE 266(24):1268-& COHEN S THALIDOMIDE POLYNEUROPATHY | 8 | 10 |
| 395 | 27 | 42 | 1124 1994 BONE MARROW TRANSPLANTATION 14(6):937-942 COLE CH; ROGERS PCJ; PRITCHARD S; PHILLIPS G; CHAN KW THALIDOMIDE IN THE MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN FOLLOWING BONE-MARROW TRANSPLANTATION | 25 | 30 |
| 396 | 0 | 0 | 1505 1999 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
| 397 | 7 | 29 | 2259 2002 LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
| 398 | 7 | 29 | 2560 2003 SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 5 |
| 399 | 0 | 0 | 1636 2000 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
| 400 | 37 | 44 | 1954 2001 JOINT BONE SPINE 68(6):582-587 Combe B Thalidomide: new indications? | 1 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 401 | 0 | 0 | 2374 2003 BLOOD 102(11):450A-451A Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M; Filippa DA; Nimer SD Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma. | 0 | 0 |
| 402 | 0 | 0 | 1491 1999 ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
| 403 | 6 | 15 | 426 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(2):150-& COOK MJ; MOORE DF EFFECT OF THALIDOMIDE ON DEVELOPING RAT FOETUS | 1 | 4 |
| 404 | 11 | 47 | 2282 2002 PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
| 405 | 0 | 0 | 2349 2003 BLOOD 102(11):259B-259B Cooper BW; Koc ON; Lazarus HM; Laughlin MJ; Myerson HJ; Creger RJ Phase II study of fludarabine, carboplatin, topotecan, and thalidomide for patients with acute myelogenous leukemia and advanced myelodysplastic syndromes. | 0 | 0 |
| 406 | 0 | 0 | 1714 2000 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
| 407 | 10 | 48 | 1563 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 77 | 122 |
| 408 | 0 | 0 | 1432 1998 EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
| 409 | 30 | 79 | 1487 1999 ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
| 410 | 8 | 21 | 1286 1996 MOLECULAR MEDICINE 2(4):506-515 Corral LG; Muller GW; Moreira AL; Chen YX; Wu MD; Stirling D; Kaplan G Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity | 43 | 62 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 411 | 4 | 7 | 2196 2002 HAEMATOLOGICA 87(3):327-328 Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M Advantages of using thalidomide for the management of patients with refractory myeloma | 3 | 4 |
| 412 | 4 | 10 | 2462 2003 HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
| 413 | 5 | 34 | 2425 2003 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 1 | 5 |
| 414 | 0 | 0 | 1412 1998 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
| 415 | 0 | 0 | 2116 2002 BLOOD 100(11):477B-477B Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). | 0 | 0 |
| 416 | 2 | 3 | 1220 1995 PRESSE MEDICALE 24(1):40-40 COUDERC LJ; MATHEZ D; LEIBOWITCH J; AUTRAN B; CAUBARRERE I PROLONGED THALIDOMIDE TREATMENT IN AN HIV-INFECTED PATIENT | 0 | 1 |
| 417 | 5 | 22 | 500 1970 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 7(2):241-& COULSON AS; SUMMERS LJ; LINDAHLK.K; TUCKER D; HELLMANN K EFFECT OF 2 SOLUBLE THALIDOMIDE DERIVATIVES ON LYMPHOCYTE STIMULATION | 16 | 17 |
| 418 | 5 | 5 | 2671 2004 MEDICAL JOURNAL OF AUSTRALIA 180(7):366-367 Coutsouvelis J; Corallo CE Thalidomide-induced bradycardia and its management | 0 | 0 |
| 419 | 3 | 6 | 820 1983 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 7(8-9):751-751 COUZIGOU P; DOUTRE MS; HOUDEE G; RICHARDMOLARD B; FLUERY B; AMOURETTI M; BEYLOT C; BERAUD C THALIDOMIDE IN THE TREATMENT OF BEHCETS SYNDROME | 0 | 9 |
| 420 | 11 | 33 | 995 1989 JOURNAL OF AUTOIMMUNITY 2(2):197-202 CRAIN E; MCINTOSH KR; GORDON G; PESTRONK A; DRACHMAN DB THE EFFECT OF THALIDOMIDE ON EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS | 7 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 421 | 0 | 0 | 678 1978 NEW SCIENTIST 77(1088):277-279 CRAWFORD C FRESH CONCERN OVER THALIDOMIDE | 0 | 0 |
| 422 | 6 | 21 | 574 1973 LANCET 2(7828):567-568 CRAWFORD CL TREATMENT OF ERYTHEMA-NODOSUM LEPROSUM WITH THALIDOMIDE | 5 | 5 |
| 423 | 0 | 8 | 577 1973 LANCET 2(7839):1201-1202 CRAWFORD CL THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM | 0 | 2 |
| 424 | 5 | 8 | 900 1985 LANCET 2(8450):331-331 CRAWFORD CL THALIDOMIDE AND LEPROSY | 1 | 1 |
| 425 | 4 | 8 | 1038 1991 BRITISH MEDICAL JOURNAL 302(6792):1603-1604 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 6 | 7 |
| 426 | 5 | 10 | 1040 1991 BRITISH MEDICAL JOURNAL 303(6809):1062-1063 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 0 | 0 |
| 427 | 5 | 5 | 1073 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 CRAWFORD CL THALIDOMIDE NEUROPATHY | 5 | 6 |
| 428 | 32 | 85 | 1115 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(4):177-192 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 8 | 11 |
| 429 | 5 | 5 | 1127 1994 BRITISH MEDICAL JOURNAL 308(6941):1437-1438 CRAWFORD CL SAFETY OF THALIDOMIDE | 4 | 4 |
| 430 | 4 | 5 | 1287 1996 NATURE MEDICINE 2(2):132-132 Crawford CL Thalidomide neuropathy | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 431 | 2 | 4 | 2263 2002 MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Crawford CL Thalidomide-induced neuropathy | 1 | 1 |
| 432 | 2 | 5 | 2655 2004 LANCET 363(9424):1911-1911 Crawford CL Does thalidomide have a role in leprosy? | 0 | 0 |
| 433 | 0 | 2 | 2669 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):199-200 Crawford CL Licensing thalidomide in Australia | 0 | 0 |
| 434 | 1 | 5 | 1459 1998 LANCET 351(9115):1591-1591 Critchley EMR Was the thalidomide tragedy preventable? | 0 | 0 |
| 435 | 0 | 0 | 2039 2002 ARTHRITIS AND RHEUMATISM 46(9):S290-S290 Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GRV Thalidomide in lupus: Efficacy and toxicity are not dose-dependent. | 0 | 0 |
| 436 | 0 | 0 | 1818 2001 ARTHRITIS AND RHEUMATISM 44(9):S280-S280 Cuadrado MJ; Smith E; Gordon P; Karim Y; Khamashta MA; Hughes GRV Thalidomide: Efficacy and safety in 30 patients with lupus and skin involvement. | 0 | 0 |
| 437 | 11 | 19 | 2218 2002 JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304 Curley MJ; Hussein SA; Hassoun PM Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma | 0 | 0 |
| 438 | 0 | 2 | 529 1971 NEW ENGLAND JOURNAL OF MEDICINE 284(9):481-& CURRAN WJ THALIDOMIDE TRAGEDY IN GERMANY - END OF A HISTORIC MEDICOLEGAL TRIAL | 1 | 4 |
| 439 | 0 | 1 | 1149 1994 LANCET 343(8900):795-796 CUTLER J THALIDOMIDE REVISITED | 4 | 5 |
| 440 | 2 | 12 | 947 1987 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 413:181-187 CZEJKA MJ; KOCH HP DETERMINATION OF THALIDOMIDE AND ITS MAJOR METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 22 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 441 | 22 | 47 | 2010 2001 SEMINARS IN ONCOLOGY 28(6):597-601 D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma | 0 | 10 |
| 442 | 3 | 83 | 2288 2002 SOCIAL HISTORY OF MEDICINE 15(1):137-158 Daemmrich A A tale of two experts: Thalidomide and political engagement in the United States and West Germany | 0 | 0 |
| 443 | 0 | 0 | 2129 2002 BONE MARROW TRANSPLANTATION 29:S255-S256 Dagan L; Ovadia R; Taou D; Bar L The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team | 0 | 0 |
| 444 | 9 | 42 | 2636 2004 JOURNAL OF CLINICAL ONCOLOGY 22(13):2532-2539 Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer | 0 | 0 |
| 445 | 17 | 32 | 2472 2003 INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 0 | 0 |
| 446 | 0 | 0 | 135 1962 LANCET 2(7249):249-& DALDERUP LM THALIDOMIDE AND TEETH | 2 | 2 |
| 447 | 2 | 4 | 1882 2001 BRITISH JOURNAL OF CANCER 85:25-25 Dalgleish A; Marriott J; Czajka A; Clarke I; Dredge K; Muller G; Stirling D New thalidomide analogues; Anti-cancer, anti-angiogenic and immunostimulatory. | 0 | 0 |
| 448 | 0 | 0 | 2405 2003 BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
| 449 | 13 | 33 | 2147 2002 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 5 | 10 |
| 450 | 6 | 40 | 1198 1995 HAUTARZT 46(8):553-560 DALLAFIOR S; PUGIN P; CERNY T; BETTICHER D; SAURAT JH; HAUSER C A CASE OF CUTANEOUS LANGERHANS CELL GRANULOMATOSIS SUCCESSFULLY TREATED WITH 2-CHLORODEOXYADENOSINE AND THALIDOMIDE | 4 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 451 | 3 | 8 | 2520 2003 LEUKEMIA 17(10):2056-2057 Dalle JH; Leblond P; Decouvelaere A; Yakoub-Agha I; Preudhomme C; Nelken B; Mazingue F Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL | 0 | 0 |
| 452 | 1 | 30 | 1457 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
| 453 | 4 | 9 | 1607 2000 ACTA DERMATO-VENEREOLOGICA 80(1):24-25 Daly BM; Shuster S Antipruritic action of thalidomide | 3 | 9 |
| 454 | 10 | 11 | 2519 2003 LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
| 455 | 0 | 0 | 1200 1995 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 36(4):S225-S225 DAMATO RJ; KENYON BM FURTHER-STUDIES EXAMINING THE EFFECTS OF THALIDOMIDE ON ANGIOGENESIS | 0 | 0 |
| 456 | 0 | 0 | 1143 1994 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 35(4):1996-1996 DAMATO RJ; LOUGHMAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 0 | 0 |
| 457 | 14 | 29 | 1160 1994 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91(9):4082-4085 DAMATO RJ; LOUGHNAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 326 | 719 |
| 458 | 0 | 0 | 1348 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):4467-4467 DAmato RJ; Verheul HMW; Panigrahy D; Yuan J Combination antiangiogenic therapy with thalidomide and nonsteroidal anti-inflammatory drugs (NSAIDs) | 0 | 0 |
| 459 | 6 | 15 | 2464 2003 INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
| 460 | 5 | 37 | 2479 2003 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 461 | 37 | 61 | 1114 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(2):65-76 DARCY PF; GRIFFIN JP THALIDOMIDE REVISITED | 21 | 26 |
| 462 | 3 | 9 | 1323 1997 CLINICAL AND EXPERIMENTAL DERMATOLOGY 22(6):297-299 Darvay A; Basarab T; Russell-Jones R Thalidomide-induced toxic pustuloderma | 4 | 8 |
| 463 | 16 | 59 | 1783 2000 QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS 93(5):305-311 Davey PP; Ashrafian H New therapies for heart failure: is thalidomide the answer? | 6 | 9 |
| 464 | 9 | 18 | 1829 2001 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 48 | 91 |
| 465 | 0 | 0 | 1676 2000 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
| 466 | 2 | 10 | 271 1964 ARCHIVES OF OTOLARYNGOLOGY 80(2):136-140 DAVIGNON M; BARR B EAR ABNORMALITIES AND CRANIAL NERVE PALSIES IN THALIDOMIDE CHILDREN | 5 | 26 |
| 467 | 0 | 0 | 306 1965 ACTA PAEDIATRICA SCANDINAVICA S:79-& DAVIGNON M; HELLGREN K; JUHLIN IM THALIDOMIDE DAMAGED CHILDREN EXPERIENCES FROM EUGENIAHEMMET | 0 | 0 |
| 468 | 0 | 0 | 432 1967 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 9(6):707-& DAVIGNON M; HELLGREN K; JUHLIN IM; ATTERBAC.B DIAGNOSTIC AND HABILITATION PROBLEMS OF THALIDOMIDE-TRAUMATIZED CHILDREN WITH MULTIPLE HANDICAPS | 2 | 2 |
| 469 | 0 | 0 | 567 1973 DRUG & COSMETIC INDUSTRY 113(3):35-& DAVIS DA GREATEST TRAGEDY - THALIDOMIDE TOLL CLEARER NOW | 0 | 0 |
| 470 | 10 | 48 | 2552 2003 RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 29(3):481-+ Davis JC; Huang F; Maksymowych W New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 471 | 0 | 0 | 1107 1993 NEW SCIENTIST 137(1862):6-6 DAYTON L THALIDOMIDE HERO FOUND GUILTY OF SCIENTIFIC FRAUD | 0 | 0 |
| 472 | 0 | 15 | 624 1976 JOURNAL OF THE INDIAN CHEMICAL SOCIETY 53(10):1049-1052 DE AU; PAL D QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR) AND RATIONAL DRUG DESIGN FOR SOME ANTINEOPLASTIC THALIDOMIDE AND GLUTARIMIDE DERIVATIVES | 0 | 10 |
| 473 | 14 | 17 | 1599 1999 REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 8 |
| 474 | 4 | 5 | 1527 1999 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
| 475 | 2 | 4 | 1474 1998 PALLIATIVE MEDICINE 12(3):208-209 Deaner P Thalidomide for distressing night sweats in advanced malignant disease | 12 | 13 |
| 476 | 2 | 4 | 1781 2000 PALLIATIVE MEDICINE 14(5):429-431 Deaner PB The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report | 0 | 1 |
| 477 | 1 | 2 | 248 1963 NATURE 199(489):1204-& DEBOCK CA; PETERS A EFFECT OF THALIDOMIDE ON DEVELOPMENT OF CHICK EMBRYO | 7 | 11 |
| 478 | 13 | 40 | 1018 1990 JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 49(6):564-581 DEIONGH RU A QUANTITATIVE ULTRASTRUCTURAL-STUDY OF MOTOR AND SENSORY LUMBOSACRAL NERVE ROOTS IN THE THALIDOMIDE-TREATED RABBIT FETUS | 3 | 3 |
| 479 | 0 | 0 | 951 1987 TERATOLOGY 36(1):A8-A9 DEIONGH RU; MCCREDIE J QUANTITATIVE NEUROPATHOLOGY OF THE PERIPHERAL-NERVES IN RABBIT THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 480 | 5 | 5 | 278 1964 BULLETIN OF THE JOHNS HOPKINS HOSPITAL 115(3):223-& DEKKER A; MEHRIZI A USE OF THALIDOMIDE AS TERATOGENIC AGENT IN RABBITS | 9 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 481 | 0 | 1 | 357 1965 TOXICOLOGY AND APPLIED PHARMACOLOGY 7(3):481-& DELAHUNT CS; KISS N; FELDMAN E; OAKES M SOME COMPARATIVE PHARMACOLOGICAL STUDIES IN MAN AND MONKEY WITH THALIDOMIDE | 3 | 6 |
| 482 | 8 | 13 | 303 1964 SCIENCE 146(364):1300-& DELAHUNT CS; LASSEN LJ THALIDOMIDE SYNDROME IN MONKEYS | 25 | 60 |
| 483 | 10 | 14 | 1204 1995 JOURNAL OF LIQUID CHROMATOGRAPHY 18(2):297-309 DELON A; FAVRELIERE S; COUET W; COURTOIS PH; BOUQUET S RAPID AND SENSITIVE DETERMINATION OF THALIDOMIDE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 5 | 5 |
| 484 | 0 | 0 | 874 1985 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 112(1):90-90 DELSOL G; DUPRE A; VIRABEN R ROSAI-DORFMAN HISTIOCYTOSIS IN A PURE CUTANEOUS FORM - THE THERAPEUTIC USE OF THALIDOMIDE | 0 | 0 |
| 485 | 20 | 46 | 2488 2003 JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
| 486 | 2 | 3 | 1237 1996 ARCHIVES OF DERMATOLOGY 132(11):1392-1393 Dereure O; BassetSeguin N; Guilhou JJ Erosive lichen planus: Dramatic response to thalidomide | 14 | 24 |
| 487 | 6 | 43 | 2148 2002 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 14 |
| 488 | 0 | 1 | 580 1973 SOCIAL CASEWORK 54(7):430-431 DESAIX CC ABNORMALITY AND NORMALITY - MOTHERING OF THALIDOMIDE CHILDREN - ROSKIES,E | 0 | 0 |
| 489 | 7 | 11 | 968 1988 FUNDAMENTAL & CLINICAL PHARMACOLOGY 2(6):493-497 DESCOTES J; TEDONE R; EVREUX JC ENHANCEMENT OF ANTIBODY-RESPONSE AND DELAYED-TYPE HYPERSENSITIVITY BY THALIDOMIDE IN MICE | 3 | 3 |
| 490 | 0 | 0 | 1213 1995 MOLECULAR BIOLOGY OF THE CELL 6:1195-1195 DESESSO JM; HARRIS SB; SCIALLI AR; GOERINGER GC EARLY MICROSCOPIC OBSERVATIONS OF THALIDOMIDE-INDUCED LIMB DEFECTS IN NEW-ZEALAND WHITE-RABBITS | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 491 | 0 | 0 | 1517 1999 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
| 492 | 12 | 25 | 2009 2001 SEMINARS IN ONCOLOGY 28(6):593-596 Desikan RK; Jagannath S Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions | 2 | 2 |
| 493 | 0 | 0 | 2 1959 BRITISH MEDICAL JOURNAL 2(OCT3):635-635 DESOUZA LP THALIDOMIDE | 2 | 3 |
| 494 | 0 | 0 | 2088 2002 BLOOD 100(11):384B-384B Devabhaktuni YD; Laber DA Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma. | 0 | 0 |
| 495 | 10 | 14 | 1292 1996 PEDIATRIC INFECTIOUS DISEASE JOURNAL 15(5):465-467 DeVincenzo JP; Burchet SK Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers | 5 | 7 |
| 496 | 0 | 0 | 2651 2004 JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 11(2):275A-275A Dharia SP; Steinkampf MP; Parker CR; Grubbs CJ; Crockett S The impact of thalidomide on ovarian function. | 0 | 0 |
| 497 | 2 | 8 | 1392 1998 AIDS 12(3):334-335 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus monkeys | 0 | 0 |
| 498 | 12 | 41 | 1749 2000 JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
| 499 | 0 | 0 | 2364 2003 BLOOD 102(11):385B-385B Di Raimondo F; Pennisi A; Buglio D; Fiumara P; Palumbo GA; Giustolisi R Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma. | 0 | 0 |
| 500 | 0 | 0 | 1425 1998 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 501 | 16 | 24 | 1950 2001 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631 Diggle GE Thalidomide: 40 years on | 7 | 9 |
| 502 | 0 | 2 | 142 1962 LANCET 2(7253):452-& DIJKHUIS HJ; JONGE GAD; BEKKER BV; VANCREVELD S; MONCHY GD; GREENE R; HAGENBEE.JH THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 0 |
| 503 | 0 | 1 | 240 1963 LANCET 1(729):1375-& DIJKHUIS HJ; VANDUYNE WM; BEKKER BV THALIDOMIDE AND CONGENTIAL ABNORMALITIES | 0 | 0 |
| 504 | 0 | 0 | 1845 2001 BLOOD 98(11):164A-164A Dimopoulos M; Panayiotidis P; Grigoraki V; Poziopoulos C; Xilouri I; Kiamouris C; Tassidou A; Gika D; Stefanoudaki K; Anagnostopoulos N; Anagnostou D Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. | 0 | 7 |
| 505 | 14 | 23 | 2556 2003 SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
| 506 | 0 | 0 | 2344 2003 BLOOD 102(11):148A-149A Dimopoulos MA; Anagnostopoulos A; Hamilos G; Zomas A; Efstathiou E; Grigoraki V; Poziopoulos C; Gika D; Xilouri I; Zorzou MP; Anagnostopoulos N Pulsed cyclophosphamide, thalidomide and dexamethasone: Long term follow-up of an oral regimen for previously treated patients with multiple myeloma. | 0 | 0 |
| 507 | 51 | 94 | 2483 2003 JOURNAL OF CLINICAL ONCOLOGY 21(23):4444-4454 Dimopoulos MA; Anagnostopoulos A; Weber D Treatment of plasma cell dyserasias with thalidomide and its derivatives | 1 | 2 |
| 508 | 0 | 0 | 2089 2002 BLOOD 100(11):384B-384B Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia. | 0 | 0 |
| 509 | 6 | 25 | 2559 2003 SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 2 | 3 |
| 510 | 0 | 0 | 1648 2000 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 511 | 5 | 13 | 1811 2001 ANNALS OF ONCOLOGY 12(7):991-995 Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N Thalidomide and dexamethasone combination for refractory multiple myeloma | 29 | 40 |
| 512 | 7 | 22 | 1959 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601 Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P Treatment of Waldenstrom's macroglobulinemia with thalidomide | 16 | 27 |
| 513 | 11 | 23 | 2150 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 1 | 1 |
| 514 | 6 | 20 | 1626 2000 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
| 515 | 5 | 11 | 211 1963 CANCER CHEMOTHERAPY REPORTS (29):99-102 DIPAOLO JA EFFECT OF THALIDOMIDE ON A VARIETY OF TRANSPLANTABLE TUMORS | 0 | 3 |
| 516 | 0 | 0 | 218 1963 FEDERATION PROCEEDINGS 22(2):666-& DIPAOLO JA THALIDOMIDE - INFLUENCE ON PRODUCTION OF CONGENITAL ABNORMALITIES IN MICE AND CANCER CHEMOTHERAPY | 3 | 4 |
| 517 | 6 | 10 | 220 1963 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 183(2):139-& DIPAOLO JA CONGENITAL MALFORMATION IN STRAIN A MICE - ITS EXPERIMENTAL PRODUCTION BY THALIDOMIDE | 0 | 41 |
| 518 | 7 | 18 | 269 1964 ANATOMICAL RECORD 149(1):149-& DIPAOLO JA; PICKREN J; GATZEK H MALFORMATIONS INDUCED IN MOUSE BY THALIDOMIDE | 9 | 18 |
| 519 | 0 | 3 | 302 1964 SCIENCE 144(362):1583-& DIPAOLO JA; WENNER CE THALIDOMIDE - EFFECTS ON EHRLICH ASCITES TUMOR CELLS IN VITRO | 4 | 9 |
| 520 | 0 | 0 | 2108 2002 BLOOD 100(11):398A-398A Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis. | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 521 | 8 | 13 | 2307 2003 AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS 10(4):257-261 Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Witzig TE; Fonseca R; Lust JA; Greipp PR; Kyle RA; Gertz MA Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis | 0 | 0 |
| 522 | 24 | 35 | 1523 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
| 523 | 4 | 26 | 2257 2002 LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
| 524 | 0 | 0 | 1669 2000 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
| 525 | 0 | 0 | 2093 2002 BLOOD 100(11):387B-387B Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M Toxicity of thalidomide in multiple myeloma patients (long-term observations). | 0 | 0 |
| 526 | 2 | 10 | 1997 2001 POLISH JOURNAL OF PHARMACOLOGY 53(6):709-713 Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M Influence of thalidomide on Bcl(2) expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients | 0 | 0 |
| 527 | 0 | 0 | 1854 2001 BLOOD 98(11):296B-297B Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M; Domanski D Influence of thalidomide on bcl-2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow lymphocyte subsets of multiple myeloma patients. | 0 | 0 |
| 528 | 11 | 14 | 2411 2003 BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
| 529 | 0 | 0 | 816 1983 CLINICAL RESEARCH 31(5):A920-A920 DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE; MILLIKAN LE THALIDOMIDE INDUCED ALTERATION OF HUMAN PERIPHERAL-BLOOD MONOCYTE ACTIVITY | 3 | 3 |
| 530 | 0 | 0 | 2247 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 531 | 0 | 0 | 1331 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PIV89-PIV89 Donahue SR; Collins JM; Flockhart DA; Abernethy DR; Trapnell CB Thalidomide pharmacokinetics do not change with chronic administration | 0 | 0 |
| 532 | 0 | 0 | 2331 2003 ARTHRITIS AND RHEUMATISM 48(9):S587-S587 Doria A; Briani C; Zara G; Rondinone R; Ermani M; Della Libera S; Ghirardello A; Zampieri S; Tedesco S Prospective study on thalidomide-induced peripheral neuropathy in SLE. | 0 | 0 |
| 533 | 0 | 1 | 1981 2001 NATURE 410(6827):411-412 Dormandy T Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 534 | 0 | 0 | 520 1971 ENVIRONMENT 13(10):50-& DOUGHERT.RC THALIDOMIDE | 0 | 0 |
| 535 | 11 | 19 | 2052 2002 BJU INTERNATIONAL 89(6):591-595 Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide | 1 | 4 |
| 536 | 0 | 0 | 1644 2000 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
| 537 | 0 | 0 | 2069 2002 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
| 538 | 8 | 20 | 2407 2003 BRITISH JOURNAL OF CANCER 88(6):822-827 Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer | 3 | 9 |
| 539 | 22 | 30 | 2318 2003 ANTI-CANCER DRUGS 14(5):331-335 Dredge K; Dalgleish AG; Marriott JB Thalidomide analogs as emerging anti-cancer drugs | 2 | 6 |
| 540 | 61 | 82 | 2168 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 541 | 10 | 36 | 2134 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 9 | 15 |
| 542 | 0 | 0 | 2457 2003 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
| 543 | 23 | 42 | 2231 2002 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 13 | 28 |
| 544 | 8 | 27 | 1971 2001 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226 Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial | 1 | 7 |
| 545 | 6 | 14 | 355 1965 TOXICOLOGY AND APPLIED PHARMACOLOGY 7(2):165-& DROBECK HP; COULSTON F; CORNELIU.D EFFECTS OF THALIDOMIDE ON FETAL DEVELOPMENT IN RABBITS AND ON ESTABLISHMENT OF PREGNANCY IN MONKEYS | 5 | 19 |
| 546 | 12 | 35 | 2536 2003 MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
| 547 | 11 | 41 | 2682 2004 PATHOLOGY INTERNATIONAL 54(5):285-294 Du WL; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment | 0 | 0 |
| 548 | 8 | 13 | 437 1967 LANCET 1(7489):569-& DUKOR P; DIETRICH FM IMMUNOSUPRESSION BY THALIDOMIDE | 10 | 13 |
| 549 | 0 | 0 | 877 1985 AUSTRALIAN PAEDIATRIC JOURNAL 21(4):295-295 DUNLOP GM; MCCREDIE J QUANTITATIVE NEUROLOGICAL CHANGES IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 550 | 5 | 17 | 1550 1999 IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 551 | 8 | 29 | 1378 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
| 552 | 8 | 15 | 2245 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(2):S193-S195 Duong DHJ; Moxley RT; Kellman RM; Pincus SH; Gaspari AA Thalidomide therapy for cicatricial pemphigoid | 0 | 0 |
| 553 | 44 | 53 | 1489 1999 ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 19 | 28 |
| 554 | 5 | 31 | 2287 2002 SEMINARS IN ONCOLOGY 29(6):34-38 Durie BGM Low-dose thalidomide in myeloma: Efficacy and biologic significance | 5 | 7 |
| 555 | 0 | 0 | 1512 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
| 556 | 0 | 0 | 1843 2001 BLOOD 98(11):163A-163A Durie BGM; Stepan DE Low dose thalidomide alone and in combination: Long term follow-up. | 0 | 6 |
| 557 | 1 | 33 | 1825 2001 BIOMEDICAL CHROMATOGRAPHY 15(3):202-206 Duval R; Leveque H; Prigent Y; Aboul-Enein HY Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases | 1 | 4 |
| 558 | 12 | 26 | 337 1965 JOURNAL OF EMBRYOLOGY AND EXPERIMENTAL MORPHOLOGY 13:181-& DWORNIK JJ; MOORE KL SKELETAL MALFORMATIONS IN HOLTZMAN RAT EMBRYO FOLLOWING ADMINISTRATION OF THALIDOMIDE | 5 | 11 |
| 559 | 4 | 15 | 522 1971 EXPERIENTIA 27(6):671-& ECKERT T; DORR NW INTERMOLECULAR INTERACTIONS OF FOLIC ACID WITH N-PHTHALOYL-DL-GLUTAMIC ACID PROBLEM OF TERATOGENIC ACTION OF THALIDOMIDE | 1 | 2 |
| 560 | 0 | 0 | 1719 2000 GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 561 | 0 | 7 | 636 1977 ACTA ORTHOPAEDICA SCANDINAVICA 48(3):273-276 EDWARDS DH; NICHOLS PJR SPINAL ABNORMALITIES IN THALIDOMIDE EMBRYOPATHY | 4 | 6 |
| 562 | 2 | 5 | 810 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 EFTHIMIOU J; SPIRO SG EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 2 | 2 |
| 563 | 0 | 0 | 2333 2003 ARTHRITIS AND RHEUMATISM 48(9):S617-S617 Efthimiou P; Rosenkranz ME; Mackenzie R; Adler R; Paget SA IVIG and thalidomide combination is an effective novel therapy for scleromyxedema. | 0 | 0 |
| 564 | 0 | 2 | 956 1988 ARCHIV DER PHARMAZIE 321(9):577-577 EGER K; BOLEWSKI J; FOLKERS G; GUTBROD O; JALALIAN M; VERSPOHL E; LUPKE NP ALPHA-PHTHALIMIDOADIPINIMIDE - SYNTHESIS, TERATOGENIC PROPERTIES AND EFFECT ON THE CENTRAL NERVOUS-SYSTEM OF A HOMO-THALIDOMIDE | 0 | 0 |
| 565 | 0 | 0 | 235 1963 LANCET 1(728):772-& EHMANN B TERATOGENIC EFFECTS OF THALIDOMIDE | 7 | 13 |
| 566 | 33 | 38 | 1090 1993 BONE MARROW TRANSPLANTATION 12:S26-S28 EHNINGER G; EGER K; STUHLER A; SCHULER U THALIDOMIDE - THE NEED FOR A NEW CLINICAL-EVALUATION OF AN OLD DRUG | 7 | 8 |
| 567 | 21 | 33 | 1543 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 131 |
| 568 | 5 | 19 | 1397 1998 ANNALS OF INTERNAL MEDICINE 128(6):494-495 Ehrlich GE Behcet disease and the emergence of thalidomide | 4 | 19 |
| 569 | 0 | 0 | 1702 2000 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
| 570 | 22 | 24 | 2223 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 571 | 13 | 38 | 1681 2000 BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 76 | 127 |
| 572 | 4 | 12 | 1775 2000 ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
| 573 | 10 | 11 | 948 1987 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 64(3):289-292 EISENBUD L; HOROWITZ I; KAY B RECURRENT APHTHOUS STOMATITIS OF THE BEHCETS TYPE - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 7 | 18 |
| 574 | 2 | 13 | 2610 2004 CLINICAL AND EXPERIMENTAL DERMATOLOGY 29(3):268-270 Eisman S; Orteu CH Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment | 0 | 0 |
| 575 | 0 | 0 | 1494 1999 ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
| 576 | 0 | 0 | 2370 2003 BLOOD 102(11):443A-443A El-Sherbiny YM; Davies FE; Cook G; Johnson RJ; Cullen MJ; Sah A; Rawstron AC; Richards SJ; Morgan GJ NK cell repertoire in myeloma and the impact of thalidomide. | 0 | 0 |
| 577 | 12 | 20 | 1383 1997 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 84(4):362-364 Elad S; Galili D; Garfunkel AA; Or R Thalidomide-induced perioral neuropathy | 2 | 3 |
| 578 | 8 | 18 | 2639 2004 JOURNAL OF IMMUNOTHERAPY 27(4):259-264 Elaraj DM; White DE; Steinberg SM; Haworth K; Rosenberg SA; Yang JC A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma | 0 | 0 |
| 579 | 0 | 0 | 2394 2003 BLOOD 102(11):923A-924A Elliott MA; Geyer SM; Camoriano JK; Kahanic SP; Alexander SJ; Medgyesy DC; Li CY; Tefferi A Low dose thalidomide (Td) treatment in myelofibrosis with myeloid metaplasia (MMM): An NCCTG study. | 0 | 0 |
| 580 | 0 | 0 | 1871 2001 BLOOD 98(11):627A-627A Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt R; Geyer GM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia (MMM). | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 581 | 12 | 36 | 2136 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 12 | 21 |
| 582 | 0 | 19 | 578 1973 PLASTIC AND RECONSTRUCTIVE SURGERY 51(1):93-95 ELSAHY NI MOBIUS SYNDROME ASSOCIATED WITH MOTHER TAKING THALIDOMIDE DURING GESTATION - CASE REPORT | 0 | 12 |
| 583 | 1 | 2 | 2534 2003 MEDICAL JOURNAL OF AUSTRALIA 178(8):413-413 Elwood JM Thalidomide and cancer? | 0 | 0 |
| 584 | 11 | 14 | 1011 1990 EUROPEAN SURGICAL RESEARCH 22(6):336-339 EMRE S; SUMRANI N; HONG J BENEFICIAL EFFECT OF THALIDOMIDE AND CICLOSPORIN COMBINATION IN HETEROTOPIC CARDIAC TRANSPLANTATION IN RATS | 5 | 5 |
| 585 | 0 | 0 | 1722 2000 HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
| 586 | 13 | 38 | 2192 2002 GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 12 |
| 587 | 8 | 31 | 2297 2003 ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 27(8):2S-6S Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N Protective effect of thalidomide on endotoxin-induced liver injury | 0 | 1 |
| 588 | 1 | 4 | 651 1977 LANCET 1(8005):251-251 ERAVELLY J; WATERS MFR THALIDOMIDE IN WEBER-CHRISTIAN DISEASE | 32 | 37 |
| 589 | 10 | 33 | 2607 2004 CELL BIOLOGY INTERNATIONAL 28(3):237-242 Ergun MA; Konac E; Erbas D; Ekmekci A Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells | 0 | 1 |
| 590 | 5 | 5 | 1326 1997 CLINICAL CHEMISTRY 43(6):1094-1095 Eriksson T; Bjorkman S Handling of blood samples for determination of thalidomide | 6 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 591 | 6 | 9 | 1060 1992 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 582(1-2):211-216 ERIKSSON T; BJORKMAN S; FYGE A; EKBERG H DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION | 43 | 43 |
| 592 | 68 | 87 | 1924 2001 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
| 593 | 21 | 27 | 1451 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 23 | 24 |
| 594 | 19 | 25 | 1181 1995 CHIRALITY 7(1):44-52 ERIKSSON T; BJORKMAN S; ROTH B; FYGE A; HOGLUND P STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE | 56 | 79 |
| 595 | 13 | 23 | 1424 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
| 596 | 28 | 36 | 1750 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
| 597 | 13 | 23 | 2497 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
| 598 | 4 | 6 | 1076 1992 TRANSPLANTATION PROCEEDINGS 24(6):2560-2561 ERIKSSON T; RIESBECK K; OSTRAAT O; EKBERG H; BJORKMAN S DRUG EXPOSURE AND FLOW-CYTOMETRY ANALYSES IN A THALIDOMIDE TREATMENT SCHEDULE THAT PROLONGS RAT CARDIAC GRAFT-SURVIVAL | 6 | 7 |
| 599 | 7 | 12 | 1611 2000 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 57(17):1607-1610 Eriksson T; Wallin R; Hoglund P; Roth B; Qi ZQ; Ostraat O; Bjorkman S Low bioavailability of rectally administered thalidomide | 2 | 2 |
| 600 | 7 | 28 | 2030 2002 ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 10 | 21 |
Page 2: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22